Type 2 inflammation occurs in a large subgroup of asthmatics, and novel cytokine-directed therapies are being developed to treat this population. In mouse models, interleukin-33 (IL-33) activates lung resident innate lymphoid type 2 cells (ILC2s) to initiate airway type 2 inflammation. In human asthma, which is chronic and difficult to model, the role of IL-33 and the target cells responsible for persistent type 2 inflammation remain undefined. Full-length IL-33 is a nuclear protein and may function as an "alarmin" during cell death, a process that is uncommon in chronic stable asthma. We demonstrate a previously unidentified mechanism of IL-33 activity that involves alternative transcript splicing, which may operate in stable asthma. In human airway epithelial cells, alternative splicing of the IL-33 transcript is consistently present, and the deletion of exons 3 and 4 (Δ exon 3,4) confers cytoplasmic localization and facilitates extracellular secretion, while retaining signaling capacity. In nonexacerbating asthmatics, the expression of Δ exon 3,4 is strongly associated with airway type 2 inflammation, whereas full-length IL-33 is not. To further define the extracellular role of IL-33 in stable asthma, we sought to determine the cellular targets of its activity. Comprehensive flow cytometry and RNA sequencing of sputum cells suggest basophils and mast cells, not ILC2s, are the cellular sources of type 2 cytokines in chronic asthma. We conclude that IL-33 isoforms activate basophils and mast cells to drive type 2 inflammation in chronic stable asthma, and novel IL-33 inhibitors will need to block all biologically active isoforms.
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interleukin-33 | alternative splicing | type 2 inflammation | asthma | basophils T ype 2 inflammation is a dominant mechanism of asthma (1) , and interleukin 33 (IL-33), IL-25, and thymic stromal lymphopoietin (TSLP) are epithelial cell cytokines that regulate type 2 responses (2). IL-33 signals through the ST2 receptor (ST2L) (3, 4) and is inhibited by a soluble decoy variant of the receptor (sST2) (5, 6) . Multiple cell types secrete type 2 cytokines in response to IL-33, including CD4 + Th2 cells, basophils, mast cells, and innate lymphocyte type 2 (ILC2) cells (7) (8) (9) (10) (11) (12) . Type 2 airway inflammation occurs in many, but not all, asthmatics (1, 13) and persists chronically in patients with the Th2-high or type 2-high asthma endotype (14) .
In mouse models of asthma, activation of ILC2s by IL-33 initiates type 2 airway inflammation (15) (16) (17) . Much less is known about how IL-33 might regulate persistent type 2 inflammation in chronic stable type 2-high asthma. IL-33 is a nuclear protein without a signal sequence, and the mechanism of its extracellular release in the airway is poorly understood. In some settings, IL-33 is released from cell nuclei during necrosis and necroptosis (18) , a process that might feature prominently during virus-induced asthma exacerbations (19) . This mechanism is unlikely to operate in the airways of stable asthmatics. Another possibility is that alternative splicing of IL33 mRNA produces proteins that localize to the cytoplasm and are capable of release from living cells (20, 21) . In support of this idea, studies have demonstrated that extracellular IL-33 release is dependent on increases in intracellular calcium concentrations, which can be induced by exogenous ATP administration (22) (23) (24) . Moreover, it is not yet clear which cell type responds to IL-33 to sustain persistent type 2 inflammation in the airway. Like ILC2s and Th2 cells, mast cells and basophils also express ST2L and secrete type 2 cytokines when activated by IL-33 (9, 25) . Some studies have found an increase in ILC2s in human asthma (26, 27) , whereas others have shown prominent gene signatures for mast cells and basophils in airway biospecimens from type 2-high asthmatics (13, 28, 29) .
Here we explore the mechanisms of persistent airway type 2 inflammation in type 2-high asthma with a focus on the IL-33/ST2 axis. We examine alternative splicing of IL33 in airway epithelial cells and explore which IL-33-responsive cells promote persistent type 2 inflammation in asthma.
Methods
Analysis of Banked Biospecimens in the University of California, San Francisco Airway Tissue Bank. To examine the cellular localization of IL-33 and to quantify IL33 transcripts in the airway, we studied histological sections from airway mucosal biopsies and epithelial brushing RNA from healthy and asthmatic subjects in the University of California, San Francisco (UCSF) Airway Tissue Bank (ATB) (SI Appendix, Table S1 ). One-step PCR and molecular cloning and sequencing were used to identify alternatively spliced variants of IL33. RNase H-dependent Significance Type 2 inflammation occurs in a large subgroup of asthmatics and is the target of multiple novel therapies for asthma; however, the mechanisms that drive type 2 inflammation in chronic asthma are poorly understood. In this study, we identify a previously unidentified mechanism of IL-33 activity involving alternative RNA transcript splicing and provide evidence that mast cells and basophils are major cellular targets of IL-33 activity driving type 2 cytokine production in stable asthma. These data advance our understanding of the mechanisms of type 2-high asthma and guide the selection of asthmatics likely to benefit from IL-33 inhibitor therapies.
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To whom correspondence may be addressed: erin.gordon@ucsf.edu or john.fahy@ucsf.edu. quantitative PCR (qPCR) was used to quantitatively measure IL33 spliced transcripts (30) . Details about subject characterization, immunostaining, and PCR are provided in SI Appendix.
In Vitro Characterization of IL-33 Isoforms. To assess the function of IL-33 isoforms, full-length and alternatively spliced IL33 cDNA were cloned into CMV promoter-driven mammalian expression vectors with and without fluorescent protein tags or EF1α promoter-driven lentiviral mammalian expression vectors with a fluorescent protein tag. Tagged and untagged CMV promoter-driven plasmids were transfected into the cultured human primary epithelial cells to determine cellular localization. IL-33 isoforms were translated in vitro by using CMV promoter-driven plasmids or expressed in Escherichia coli and used to determine cytokine bioactivity. EF1α promoter-driven mammalian lentiviral expression vectors were used to create stable Beas2B-overexpressing epithelial cell lines to study IL-33 secretion. Details of the cell culture methods, immune assays, and the IL-33 bioactivity assay are provided in SI Appendix.
Analysis of Cells in Induced Sputum. To characterize ST2-bearing cells in the airway, we applied FACS and qPCR to prospectively collected samples of induced sputum from asthmatic subjects and healthy controls (SI Appendix, Table S2 ). We also stimulated sputum cells with cytokines in vitro and analyzed the response using RNA sequencing. Protocol visit details are described in SI Appendix, as are methods of sputum cell FACS, PCR, and stimulation.
Study Approval. All subjects provided written informed consent for the study in which they originally participated and also provided written informed consent for their biospecimens to be placed in the UCSF ATB for studies in addition to the original protocol. All studies and UCSF ATB procedures were reviewed and approved by the UCSF Committee on Human Research. Statistical Analysis. Two group comparisons were made with the paired Student t test, and three or more group differences were assessed by using ANOVA with Bonferroni corrections for multiple comparisons. qPCR gene expression data were normalized and log2 transformed. Linear regression models were used to assess the relationship between different biologic splice variants of IL-33 and airway type 2 inflammation. Models were constructed with adjustment for age, gender, and inhaled corticosteroid use. Regression models were performed by using robust SEs. Simple correlations were made with Spearman's rank order correlation. Flow-cytometric data were analyzed by nonparametric t test because of the nonnormal distribution, and data are displayed as median ± interquartile range. All statistical analyses were performed in either STATA/SE (Version 11.0) or GraphPad Prism (Version 5.0d).
Results

IL-33 Localizes to Epithelial Cells and Endothelial Cells in the Airway.
We examined protein expression of IL-33 using immunofluorescence in sections of airway biopsies collected during research bronchoscopy. We found that IL-33 localizes predominantly to epithelial and endothelial cells within the airway ( Previous studies in cell lines, primary human keratinocytes, fibroblasts, and endothelial cells indicated that exons 3, 4, and 5 can be alternatively spliced out of the IL33 transcript (20) . To evaluate IL33 splicing patterns in human airway epithelial cells, we generated cDNA amplicons spanning exons 2-8 using RNA extracted from epithelial brushings from human subjects. Four distinct PCR product bands were expressed in all samples ( S3A ). Each assay was specific for and linearly amplified its target (SI Appendix, Figs. S3B and S4). After correcting for primer efficiency, we found that full-length IL33 mRNA was the most highly expressed variant, followed by Δexon 3,4; Δexon 3; Δ exon 3,4,5; and Δ exon 5 (Fig. 1C) .
Splicing of Exons 3 and 4 Results in Cytoplasmic Localization of IL-33.
To determine whether IL-33 splice variant proteins localize to different cellular compartments, we overexpressed the 10 variants in primary human airway epithelial cells using constructs tagged with a fluorescent protein. Full-length IL-33 localized exclusively to the cell nucleus ( Fig. 2A) . In contrast, Δ exon 3,4 localized to the nucleus and the cytoplasm (Fig. 2A) . Deletion of either exon 3 or 4 alone resulted in localization predominantly in the nucleus (Fig. 2A) . The Δ exon 3,4,5 colocalized with an autophagosome marker (LC3B) (Fig. 2A) . The cellular localization of untagged proteins was similar to that of the tagged proteins (SI Appendix, Fig. S5 ). Multiple alternatively spliced transcripts of IL33 are detectable in airway epithelial RNA from healthy subjects (n = 10). Exons 2-8 of IL33 were reverse-transcribed, PCR-amplified, and analyzed on an Agilent 2100 Bioanalyzer. Splicing out of some or all of exons 3, 4, and 5 are revealed by cloning and sequencing of cDNA generated from airway epithelial cell RNA from human subjects (SI Appendix, Fig. S2 ). (C) By using RNase H-dependent primers, full-length IL33 is the most abundant transcript in airway epithelial brushings, but multiple IL33 isoforms are also highly expressed. The data are from airway epithelial brushings from 39 healthy controls and are corrected for primer efficiency (median ± interquartile range).
Exon 5 Is Required for IL-33 Cytokine Activity. To determine whether IL-33 splice variants retain their ability to signal via the ST2 receptor, we generated proteins using in vitro transcription and translation and examined signaling in a mast cell line (HMC-1). All IL-33 isoforms produced proteins (SI Appendix, Fig. S2B ). Fulllength IL-33 protein demonstrated cytokine activity, as did Δ exon 3, Δ exon 4, and Δ exon 3,4 splice variants, but IL-33 variants missing exon 5 did not (Fig. 2B ). This result is consistent with reports that exon 5 encodes amino acid residues that are critical for binding of IL-33 to ST2 (31) . We purified Δ exon 3,4 protein (SI Appendix, Fig. S6 ) and found that it signals in a dose-dependent manner and is inhibited by recombinant sST2 (Fig. 2C) . We demonstrate that Δ exon 3,4 protein binds avidly to recombinant ST2-Fc receptor with a K D of 0.25 nM (SI Appendix, Fig. S7A ), and stimulation of primary human basophils with Δ exon 3,4 in combination with IL-3 results in an increase of IL-13 and -5 protein production (SI Appendix, Fig. S7 B and C) . To determine whether biologically active forms of IL-33 are related to airway type 2 inflammation, we measured IL33 splice variant transcripts in epithelial brush RNA from 85 mild to moderate asthmatics with stable disease (SI Appendix, Table S1 ). These subjects previously had gene expression measured for periostin, CLCA1, and serpinB2, which are markers of airway epithelial cell activation by IL-13 (28, 32) that can be combined into a single "three-genemean" (TGM) metric (32) . Among the biologically active IL-33 splice variants, we found that Δ exon 3,4 was the only variant significantly associated with the TGM (Fig. 3 and SI Appendix, Table  S3 ). Because the TGM is decreased by inhaled corticosteroids (32), we adjusted for corticosteroid use and found that the relationship remained significant (Fig. 3 and SI Appendix, Table S3 ). Full-length IL33 was not associated with the TGM. We also measured IL-33 protein in the bronchoalveolar lavage fluid from a subset of these subjects (n = 51) and found that IL-33 levels were below the limit of detection (1.7 pg/mL) in the majority of the samples. (Fig. 4A) . Notably, full-length IL-33 protein was more abundant than Δ exon 3,4 protein in the intracellular lysates (Fig. 4B) . Although we were unable to detect IL-33 peptides in our cell culture-conditioned medium, we did detect the GFP fusion tag in the conditioned medium of both the full-length IL-33-GFPand Δ exon 3,4-GFP-overexpressing cells (Fig. 4C ) without evidence of cellular necrosis (Fig. 4D) . In both unstimulated cells and ionomycin-stimulated cells, we found that the concentration of extracellular GFP in the conditioned medium of Δ exon 3,4-GFP cells was significantly higher than in full-length IL-33-GFP cells (Fig. 4E) .
Expression of the ST2 Receptor (ST2L) Correlates with Expression of Type 2 Cytokines and Mast Cell/Basophil Genes in Sputum. IL-33 activates ST2 receptor-bearing cells to stimulate the production of type 2 cytokines, but the specific cells driving the production in type 2-high asthma are unknown. We previously found that gene expression for type 2 cytokines is increased in asthmatic sputum cells (29) . Here we measured gene expression for the ST2 receptor (A) Full-length and alternatively spliced IL33 cDNA were cloned into CMV-driven mammalian expression vectors tagged with venus fluorescent protein, and plasmids were transfected into primary human airway epithelial cells. Full-length, short 5, Δ exon 3, Δ exon 4, Δ exon 5, Δ exon 3-short 5, and Δ exon 4,5 isoforms localized to the nucleus, whereas the Δ exon 3,4 and Δ exon 3,4-short 5 isoforms localized to both the nucleus and the cytoplasm. The Δ exon 3,4,5 isoform demonstrates a punctate, perinuclear staining, which colocalized with the autophagosome marker LC3B. (B) In vitro-translated IL-33 protein isoforms show differences in signaling activity in HMC-1 cells. Whereas isoforms containing exon 5 cause release of IL-8, proteins with a deletion in exon 5 do not. (C) Recombinant purified Δ exon 3,4 IL-33 protein demonstrates cytokine bioactivity in HMC-1 cells (EC 50 : 0.8-1.1 ng/mL). The activity of Δ exon 3,4 IL-33 in HMC-1 cells is inhibited by sST2. Data in B and C represent mean ± SD for three replicates for each experimental condition. ***P < 0.001; ****P < 0.0001. Fig. 3 . The Δ exon 3,4 IL-33 transcript is associated with type 2 airway inflammation. A forest plot shows the odds ratios (x axis) for the association between the expression of 5 different IL-33 isoforms (y axis) in airway epithelial cells and airway type 2 inflammation in 85 stable asthmatic subjects. The type 2 inflammation outcome is based on a composite metric of three IL-13-responsive genes in airway epithelial cells (periostin, CLCA1, and serpinB2). The plot shows that only the Δ exon 3,4 IL33 isoform is significantly and positively associated with airway type 2 inflammation. Data presented in black are adjusted for age and gender, and data presented in red are adjusted for age, gender, and use of inhaled steroids. Δ ex 3,4-sh5 refers to Δ exon 3,4-short 5. *P < 0.05; ***P < 0.001.
(ST2L) in induced sputum cells from asthmatics and healthy controls (SI Appendix, Table S2 ) and found that ST2L expression is markedly increased in asthmatics (SI Appendix, Fig. S8 ) and is tightly correlated with a composite metric of IL4, IL5, and IL13 gene expression (Fig. 5A) . Notably, carboxypeptidase A3 (CPA3), a human mast cell and basophil protease, and tryptase, a mast cell protease, are also very strongly correlated with ST2L expression in sputum cells (Fig. 5A) Table S2 and Fig.  S9A ). We used fluorescence-minus-one controls to identify positive ST2 staining (Fig. 5B) . ST2 was observed on all of our defined cell populations, but was strongest in basophils (Lin (Fig.  5B) , which also expressed CD123 (SI Appendix, Fig. S10 ). We performed flow cytometry on concomitantly collected sputum samples and used the gating strategy defined in PBMCs to identify immune cell subsets in sputum (SI Appendix, Fig. S9B ). We found that ILC2s are rare and not increased in number in asthmatic subjects, whereas basophils are more abundant in asthmatic than in healthy subjects (Fig. 5C ). Although our gating strategy did not allow us to identify mast cells, we performed additional analysis of sputum cells in a smaller group of asthmatic subjects to confirm the presence of mast cells. We found Lin (Fig. 6A) , because these cytokines synergize in stimulating type 2 cytokine secretion from ST2 + cells (33) . Sputum cells from 6 of the 12 asthmatics showed increased IL5 and IL13 gene expression after IL-33/TSLP activation ("responders"), whereas 6 donors showed no increase ("nonresponders") (Fig. 6B) . IL4 expression was undetectable in most samples. Comparing the gene expression profiles of the responder and nonresponder sputum cells under control conditions, we found that mast cell and basophil genes (CPA3, GATA2, HDC, and KIT) were prominent among the 94 differentially expressed genes (Dataset S1), which separate the two groups in cluster analysis (SI Appendix, Fig. S11 ). Using the Human Immune Cell Transcriptome dataset (National Center for Biotechnology Information Gene Expression Omnibus), we compared the transcriptomes of six human immune cell types to the transcriptome of our responders or nonresponders in the control condition. Using gene set enrichment analysis, we found that the IL-33 responders were enriched in transcripts found in mast cells/basophils as well as B cells (Fig. 6C and SI Appendix, Fig. S12A ). The IL-33 nonresponders were enriched in transcripts found in macrophages and neutrophils ( Fig.  6C and SI Appendix, Fig. S12B ).
Discussion
In this study, we explored the mechanisms underlying persistent type 2 inflammation in asthma with a focus on the IL-33/ST2 axis. We show that a splice variant of IL-33 missing exons 3 and 4 localizes to the cytoplasm of airway epithelial cells, retains signaling capacity, is actively secreted from epithelial cells, and is strongly associated in asthma with an airway gene expression signature of type 2 cytokine activity. Among ST2-bearing sputum cells, we found that basophils are increased in asthma, and sputum cells that have a type 2 cytokine response to IL-33 in vitro have a gene profile that is enriched in genes typical of basophils and mast cells. We propose a model in which persistent type 2 inflammation in asthma results from activation of basophils and mast cells by alternatively spliced variants of IL-33 in addition to other epithelial cytokines .
Full-length IL-33 contains both nuclear localization signals and a chromatin-binding motif that explain its prominent nuclear localization (34, 35) . Extracellular release of full-length IL-33 may occur when cells undergo necrosis and necroptosis (18) , but excessive cellular necrosis is unlikely in the airways of stable asthmatics (13, 28, 29) . We considered the possibility that release of IL-33 in type 2-high asthma might involve alternatively spliced IL33 transcripts that produce proteins stored in the cytoplasm of epithelial cells. It is known that alternative splicing of IL33 mRNA produces proteins that localize to the cytoplasm (20) , but the biological activity of these splice variants and their regulation in airway disease have not been demonstrated. We found that deletion of exon 5 rendered IL-33 isoforms incapable of signaling via the ST2 receptor. Moreover, we found that deletion of exons 3 and 4 is required to confer cytoplasmic localization in primary airway epithelial cells. Among the five IL-33 isoforms that we found to be capable of cytokine signaling, only Δ exon 3,4 was strongly associated with a gene expression signature of type 2 cytokine activity in the airway in asthma. Finally, we show that, although both full-length and Δ exon 3,4 protein variants were secreted from the Beas2B cell line in the absence of cell death, the Δ exon 3,4 variant was secreted more abundantly, especially in ionomycin-stimulated cells. Literature has shown that the secretion of IL-33 from living primary airway epithelial cells is calciumdependent (22) (23) (24) . Our finding linking cytoplasmic localization and secretion of IL-33 protein to airway type 2 cytokine activity is supported by in vitro and in vivo mouse studies. Deletion of the N terminus of IL-33 results in cytoplasmic localization in HEK-293T cells (36) , and a similar N-terminal deletion causes high systemic IL-33 levels and widespread eosinophilia in mice (37) . Mechanisms that confer cytoplasmic localization, such as alternative splicing, are likely to be critical for IL-33 extracellular release. It is notable that we were unable to detect extracellular IL-33 peptides in either cell culture medium or lavage fluid, although we were able to detect extracellular GFP when we fused this tag to the IL-33 protein. Many factors may contribute to the inability to detect extracellular IL-33, including binding of IL-33 by soluble ST2, IL-33 alterations such as oxidation (38) , or proteolytic degradation (39) . These factors likely function to inactivate IL-33 signaling and limit the effects of this potent cytokine. Together, our findings that Δ exon 3,4 variant is localized to the cytoplasm and actively secreted into the extracellular space, has cytokine activity, and is associated with type 2 inflammation in asthma suggest that this variant acts as a secreted cytokine in living cells to drive type 2 inflammation. The association between airway expression of the Δ exon 3,4 variant and type 2 inflammation remained significant, despite controlling for the use of inhaled steroids. Previous reports suggest that lung IL-33 expression and secretion may be resistant to steroid treatment (40, 41) , a finding that may relate directly to Δ exon 3,4 variant expression. An important implication of our findings is that asthma treatments that aim to directly inhibit IL-33 cytokine activity will need to be designed to block this Δ exon 3,4 variant. Such therapeutics may be particularly beneficial in a population of steroid-resistant asthmatics.
We provide several lines of evidence that basophils and mast cells produce type 2 cytokines in chronic type 2-high asthma. In qPCR studies, we showed that the expression of type 2 cytokine genes in sputum cells from asthmatics is tightly correlated with the expression of ST2L and that ST2L expression is very strongly correlated with the expression of tryptase and CPA3 (proteases whose expression is restricted to basophils and mast cells). In FACS studies, we showed that basophils (but not CD4 + T cells or ILC2 cells) are increased in sputum in asthma. Our FACS strategy did not allow us to comprehensively evaluate the relative abundance of mast cells in asthmatic compared with healthy subjects; however, we documented that mast cells are present, but rare, in the sputum of asthmatics. Consistent with this finding, we previously identified mast cells in airway biopsies using immunohistochemistry and found that they interdigitate within the epithelium and are more abundant in patients with the Th2-high endotype (42) . Finally, we show that asthmatics whose sputum cells have a type 2 cytokine response to IL-33 in vitro also have a gene transcript profile enriched in the expression of genes found in basophils, mast cells, and B cells. This basophil and mast cell gene profile includes expression of proteases (tryptase and CPA3), transcription factors (GATA-2), and surface receptors (ST2L, CRLF2/TSLPR, and MS4A2). Although these markers cannot distinguish between mast cells and basophils, they provide support for the conclusion that mast cells and basophils are the key ST2-bearing cells that produce type 2 cytokines in response to IL-33.
The enrichment of B cells in this group of asthmatics may reflect the overlapping role of IgE-dependent immune responses (43, 44) . Finally, the presence of macrophage and neutrophil transcripts in the airways of asthmatics who do not demonstrate type 2 responses to IL-33 stimulation is notable. Although subgroups of asthmatics with neutrophilic airway inflammation have been described (45, 46) , it will be important to understand whether these or other associated cell types may be suppressing type 2 responses and promoting alternative inflammatory pathways in asthma. Nevertheless, our study in chronic human asthma implicates alternative splicing of IL-33 as well as basophils and mast cells in the maintenance of airway type 2 inflammation. Therapeutics targeting the IL-33 and the type 2 axis will likely benefit subjects with an accumulation of these cell types.
